FDA Clearance Tracker · P170043-S008
iStent inject Trabecular Micro-Bypass System
Last checked: Nov 20, 2026Latest source record: Mar 3, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Mar 3, 2021
Approved
Time to decision
86 days
Received Dec 7, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170043-S008
- Device name
- iStent inject Trabecular Micro-Bypass System
- Applicant
- Glaukos Corporation
- Applicant location
- San Clemente, CA
- Received
- Dec 7, 2020
- Decided
- Mar 3, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P170043
Device type
- Device type
- Intraocular pressure lowering implant (OGO)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval of the revised PAS protocol, IG2M-105-PASN to include the modified device version, Model G2-W
Source documents
Other decisions for Glaukos Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K220032 · Decided Aug 2, 2022 · 209 days after receipt
Device type: Implant, Eye Valve (KYF) · Ophthalmology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.